Vertex acquires Crinetics in $10bn endocrinology deal
Acquisition set to bolster Vertex’s rare disease portfolio with addition of two potentially best-in-class endocrine assets.
Vertex Pharmaceuticals is adding Palsonify (paltusotine) and atumelnant, two potential best-in-class Phase III candidates to its portfolio by acquiring Crinetics Pharmaceuticals for approximately $10 billion.
Palsonify is approved in the US as the first once-daily oral therapy for adults with the rare disease acromegaly, which is caused by a pituitary tumour that secretes excess growth hormone.
Atumelnant is the firm’s most advanced asset. The once-daily oral…
Already a member? Sign-in
